Risperidone Long-Acting Injectable (Lai) Suspension Suppliers & Bulk Manufacturers

Available Forms: Long-acting injectable (LAI) suspension

Available Strengths: 25 mg, 37.5 mg, 50 mg per dose

Reference Brands: Risperdal®(US & EU); EU: Risperidon-ratiopharm®, Rispolept®, Rispen®

Category: Antipsychotropic Drugs

Risperidone Long-acting injectable (LAI) suspension is available in Long-acting injectable (LAI) suspension and strengths such as 25 mg, 37.5 mg, 50 mg per dose. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Risperidone Long-acting injectable (LAI) suspension is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Risperidone Long-acting injectable (LAI) suspension can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Product Description: Risperidone Long-Acting Injectable (LAI) suspension is approved by the FDA in the United States and the EMA in the European Union for the treatment of schizophrenia and maintenance therapy in bipolar I disorder. It offers an extended-release formulation designed for intramuscular injection every two weeks or monthly, ensuring steady therapeutic levels and improving medication adherence. Regulatory bodies emphasize its importance in reducing relapse rates and hospitalizations. Prescribers must adhere to initiation protocols, especially when transitioning from oral risperidone. To explore additional forms and strengths of risperidone LAI, visit Pharmatradz.com.